Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
Want to see HK:2509 full AI Analyst Report?
Top Page
Qyuns Therapeutics Co., Ltd. Class H
(2509)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$18.00
▼(-37.02% Downside)
Action:ReiteratedDate:05/03/26
The score is supported mainly by the sharp improvement in 2025 financial performance (profitability and cash flow turning strongly positive) and a reasonable earnings multiple (P/E ~12.3). These positives are offset by a weak technical picture (price below key moving averages with negative MACD and very low Stoch/low RSI) and the risk that the turnaround is not yet proven durable given prior multi-year volatility.
Positive Factors
Sharp 2025 revenue and margin inflection
A large revenue increase combined with high operating and net margins indicates the company achieved meaningful commercial or operational leverage in 2025. Sustained margins at this scale can fund R&D and commercialization, improve reinvestment capacity, and support durable profitability if execution continues.
Negative Factors
Multi-year volatility and prior losses
A history of prolonged losses and swings in key financials implies execution and/or market risk that undermines confidence in a single-year recovery. Structural issues that produced instability previously could re-emerge, making the 2025 turnaround less reliable as a basis for long-term forecasts without multi-year confirmation.
Read all positive and negative factors
Positive Factors
Negative Factors
Sharp 2025 revenue and margin inflection
A large revenue increase combined with high operating and net margins indicates the company achieved meaningful commercial or operational leverage in 2025. Sustained margins at this scale can fund R&D and commercialization, improve reinvestment capacity, and support durable profitability if execution continues.
Read all positive factors
Qyuns Therapeutics Co., Ltd. Class H (2509) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.91B
Dividend YieldN/A
Average Volume (3M)305.01K
Price to Earnings (P/E)12.3
Beta (1Y)0.60
Revenue Growth410.53%
EPS GrowthN/A
CountryHK
Employees339
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.86
Shares Outstanding227,071,600
10 Day Avg. Volume194,489
30 Day Avg. Volume305,010
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.43
Price to Sales (P/S)4.80
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$33.50Price Target Upside17.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.72
Revenue Forecast (FY)HK$550.33M
Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Qyuns Therapeutics Co., Ltd. Class H (2509) is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases, particularly in the fields of oncology and autoimmune disorders. The company specializ...
Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
66
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 320.36M | 786.08M | 158.79M | 14.75M | 9.66M | 21.35M |
| Gross Profit | 232.06M | 664.66M | 92.19M | 14.75M | -25.85M | -9.56M |
| EBITDA | -156.69M | 351.00M | -311.82M | -484.12M | -295.51M | -155.65M |
| Net Income | -191.79M | 306.31M | -335.57M | -507.75M | -298.19M | -411.04M |
Balance Sheet | ||||||
| Total Assets | 1.13B | 1.60B | 983.88M | 795.58M | 1.16B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 558.90M | 1.04B | 556.55M | 377.25M | 689.57M | 620.44M |
| Total Debt | 635.93M | 580.26M | 527.60M | 346.06M | 295.25M | 290.26M |
| Total Liabilities | 916.32M | 921.62M | 762.83M | 494.63M | 419.55M | 444.45M |
| Stockholders Equity | 226.36M | 694.33M | 228.98M | 324.54M | 641.72M | 670.35M |
Cash Flow | ||||||
| Free Cash Flow | -213.39M | 392.23M | -186.09M | -308.63M | -301.70M | -228.64M |
| Operating Cash Flow | -211.00M | 399.85M | -186.09M | -300.68M | -275.23M | -157.60M |
| Investing Cash Flow | 109.12M | 118.69M | -25.23M | 243.11M | -5.70M | -306.69M |
| Financing Cash Flow | 133.17M | 93.73M | 351.81M | 61.21M | 211.49M | 281.48M |
Qyuns Therapeutics Co., Ltd. Class H Technical Analysis
Positive
28.58
Price Trends
19.06
Positive
19.90
Positive
21.73
Negative
Market Momentum
0.53
Negative
55.57
Neutral
55.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2509, the sentiment is Positive. The current price of 28.58 is above the 20-day moving average (MA) of 19.34, above the 50-day MA of 19.06, and above the 200-day MA of 21.73, indicating a neutral trend. The MACD of 0.53 indicates Negative momentum. The RSI at 55.57 is Neutral, neither overbought nor oversold. The STOCH value of 55.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2509.
Qyuns Therapeutics Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$6.12B | 11.60 | 2.04% | ― | 1117.02% | ― | |
60 Neutral | HK$3.91B | 12.32 | -48.44% | ― | 410.53% | ― | |
58 Neutral | HK$12.49B | -77.24 | -11.81% | ― | 219.26% | 87.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$5.51B | -31.16 | -17.64% | ― | -65.87% | 6.71% | |
44 Neutral | HK$3.92B | -10.14 | -32.79% | ― | 109.02% | 36.95% | |
41 Neutral | HK$3.19B | -9.15 | -26.73% | ― | 14.59% | 26.32% |
* Healthcare Sector Average
HK:2509
Qyuns Therapeutics Co., Ltd. Class H
17.20
5.90
52.21%
HK:6996
Antengene Corporation Limited
5.03
2.00
66.01%
HK:6998
Genor Biopharma Holdings Limited
3.05
0.85
38.64%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
7.00
3.13
80.88%
HK:2171
CARsgen Therapeutics Holdings Ltd.
21.60
5.66
35.51%
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
4.66
-1.97
-29.71%
Qyuns Therapeutics Co., Ltd. Class H Corporate Events
Qyuns Therapeutics Invests RMB270 Million in Low-Risk PDB Wealth Products
Apr 29, 2026
Qyuns Therapeutics has entered into a series of new subscription agreements with PDB to deploy idle funds into low-risk, principal-guaranteed floating-yield structured deposit products. The company will invest a combined RMB270 million across thre...
Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
Mar 27, 2026
Qyuns Therapeutics reported a sharp turnaround in its 2025 annual results, with revenue surging to RMB 806.96 million from RMB 158.79 million a year earlier and gross profit jumping to RMB 714.41 million. The company moved from a loss of RMB 349.6...
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
Mar 27, 2026
Qyuns Therapeutics has created a Strategy and Development Committee under its board to better manage the company’s long-term strategic development and major investment decisions. The move is intended to enhance core competitiveness, improve ...
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
Mar 27, 2026
Qyuns Therapeutics has formalized detailed terms of reference for its board Audit Committee to enhance decision-making and oversight of financial reporting and internal control systems. The committee is mandated to review the company’s finan...
Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
Mar 27, 2026
Qyuns Therapeutics has established a Remuneration and Appraisal Committee under its board of directors to standardize performance evaluation and pay management for directors and senior management. The committee is mandated to design assessment sta...
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
Mar 27, 2026
Qyuns Therapeutics has established a nomination committee under its board of directors to formalize and optimize the selection process for directors and senior management. The move is designed to rationalize board composition, align with PRC compa...
Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
Mar 23, 2026
Qyuns Therapeutics has subscribed to a principal-guaranteed, floating-yield wealth management product from a commercial bank, investing RMB100 million of its idle funds with a maturity date of September 23, 2026. The product offers a guaranteed an...
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
Mar 17, 2026
Qyuns Therapeutics has scheduled a board meeting for March 27, 2026 to review and approve the group’s annual results for the financial year ended December 31, 2025 and to authorize their publication. The board will also consider whether to r...
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
Mar 9, 2026
Qyuns Therapeutics announced that China’s National Medical Products Administration has accepted the new drug application for Crusekitug, an anti-IL-17A monoclonal antibody injection for adult patients with active ankylosing spondylitis. The ...
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
Feb 5, 2026
Qyuns Therapeutics has launched an on-market share repurchase program under a previously approved mandate, after its board concluded that the current share price significantly undervalues the company’s intrinsic worth and long‑term pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.